Next Article in Journal
Antimicrobial Resistance in Lactococcus spp. Isolated from Native Brazilian Fish Species: A Growing Challenge for Aquaculture
Previous Article in Journal
Community Structure and Biodiversity of Active Microbes in the Deep South China Sea
Previous Article in Special Issue
Dual-Emission Fluorescence Resonance Energy Transfer (FRET) PCR Discriminates Salmonella Pullorum and Gallinarum
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 12
Issue 11
10.3390/microorganisms12112326
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Expanded HPV Genotyping by Single-Tube Nested-Multiplex PCR May Explain HPV-Related Disease Recurrence

by
Luiz Ricardo Goulart
1,2,†,
Bruna França Matias Colombo
1,
Mayara Ingrid Sousa Lima
3,
Maria Socorro A. de Andrade
4,
Juliana São Julião
5,
Adriana Freitas Neves
6 and
Silma Regina Pereira
3,*
1
Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38400-902, MG, Brazil
2
Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA 95616, USA
3
Laboratory of Genetics and Molecular Biology, Department of Biology, Federal University of Maranhão, São Luís 65085-580, MA, Brazil
4
Health Department of the State of Maranhão, São Luís 65000-00, MA, Brazil
5
BioGenetics Tecnologia Molecular Ltda., Uberlândia 38400-446, MG, Brazil
6
Institute of Biotechnology, Federal University of Catalão, Catalão 75705-220, GO, Brazil
*
Author to whom correspondence should be addressed.
†
In memoriam.
Microorganisms 2024, 12(11), 2326; https://doi.org/10.3390/microorganisms12112326
Submission received: 9 October 2024 / Revised: 13 November 2024 / Accepted: 13 November 2024 / Published: 15 November 2024
(This article belongs to the Special Issue Detection and Identification of Pathogenic Bacteria and Viruses)
Browse Figures
Review Reports Versions Notes

Abstract

:
The role of the human papillomavirus (HPV) in the establishment of cervical cancer has driven studies to find more effective methods of viral detection so that early intervention strategies can be performed. However, the methods still have limitations, especially regarding detecting the different genotypes simultaneously. We have developed a high-throughput system using a single-tube nested-multiplex polymerase chain reaction (NMPCR) for the detection of 40 HPV genotypes using capillary electrophoresis. The NMPCR assay was compared to the Hybrid Capture 2 assay (HC2) with 40 women from the Northeast of Brazil (São Luis, MA), a high endemic region, where the HPV positivity was 75% and 37.5%, respectively. These results were validated by performing a molecular epidemiological study on 5223 Brazilian women undergoing gynecological examinations from 2009 to 2017, who presented with an HPV prevalence of 59%. Multiple infections were found in 62.5% and 58% of the patients from the endemic region and from the Brazilian women population, respectively, mostly presenting high-risk genotypes (90.5% and 60%, respectively). Considering cervical intraepithelial neoplasia and adenocarcinomas, the sensitivity and specificity were 97.5% and 100%, respectively. The NMPCR assay was also capable of identifying viral subtypes in cases of multiple infections, even with low viral loads (10−6 ng/µL of HPV DNA). The NMPCR test is a promising and robust tool for HPV diagnostics and a screening tool for prevention of cervical cancer.

1. Introduction

The human papillomavirus (HPV) is the most common sexually transmitted infection, and it has been identified as a definite human carcinogen in six types of cancer in the cervix [1], the penis [2], the vulva, the vagina, the anus, and in head and neck squamous cell carcinoma [3,4]. The World Health Organization reports that cervical cancer is the fourth largest female malignancy worldwide, affecting 662,301 women in 2022, with over 50% of these cases resulting in death [5]. In addition, the worldwide prevalence of HPV infection in women without cervical abnormalities is 11–12% [6]. Two effective prevention strategies for cervical cancer have been nominated—vaccination against the human papillomavirus (HPV) and cervical screening with primary HPV testing followed by treatment of precancerous lesions [7].
Despite the expectation of a substantial decrease in cervix cancer incidence after the implementation of the HPV vaccination programs, overall vaccination rates have been surprisingly low globally [1]. Several challenges must be addressed, particularly in developing countries, including reducing the financial cost of vaccines, incorporating adolescents into vaccination programs, and overcoming cultural barriers related to sexual education, among others [8]. It is worth mentioning that vaccination coverage is still restricted to four or nine HPV subtypes and, considering the wide and diverse distribution of the HPV genotypes in different populations, it is still mandatory for the periodic gynecological control of cervical cancer as well as the development of more efficient tools for HPV genotypes detection.
HPV DNA detection is considered the gold-standard technique, particularly when targeting the L1 structural capsid genome region. This region is conserved among different genotypes, with variations leading to the identification of more than 200 papillomavirus genotypes [9], of which approximately 100 are well characterized in humans. Among these, nearly 50 different types infect the genital tract [10], with high-risk genotypes including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, 68, 73, and 82. Other types, such as 13, 26, 30, 32, 34, 40, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 74, 81, 83, 84, CP141, CP8304, CP4173, and CP8061, present intermediate risk. In contrast, types 6, 11, 40, 42, 43, 44, 57, and CP6108 are classified as low risk and are primarily associated with anogenital warts [11,12,13,14,15].
A strong correlation between viral integration into the host DNA and invasive carcinoma has led to the increasing use of DNA detection technology as a diagnostic tool to enhance the sensitivity and accuracy of HPV DNA detection [16,17,18,19,20,21,22]. Currently, the Hybrid Capture 2 assay (HC2, Qiagen, Redwood City, CA, USA) is the most commonly used test for HPV diagnosis, but it has some disadvantages, such as the inability to perform genotyping, lack of specimen adequacy control, the requirement for a larger amount of biological material, and the potential for cross-hybridization with low-risk genotypes [23]. Real-time PCR is highly sensitive, and although it can distinguish among various genotypes, the protocol requires parallel reactions with multiple fluorescent probes. Alternatively, other methods allow simultaneous amplification of broad-range DNA regions by using general primers [16] combined with specific oligonucleotides in a technique known as nested-multiplex PCR (NMPCR) [24]. Although NMPCR has been employed in some studies for HPV detection [25,26], these efforts have been constrained to a limited range of viral types. As a result, a diagnostic assay capable of comprehensively identifying the predominant viral types that infect the genital tract has not yet been developed.
Screening for cervical cancer using DNA and cytopathology has been reviewed, and the US Preventive Services Task Force recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk HPV (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (co-testing) for women aged 30 to 65 years [27]. However, we hypothesize that the lack of sensitive and comprehensive detection of most mucosal HPV genotypes, coupled with multitype infections, may lead to shifts in the frequency of virus genotypes under specific vaccination programs in the near future. This could reduce the burden of HPV types 16, 18, 6, and 11 while increasing the likelihood of the emergence of other virus subtypes with lower prevalence in the population.
Therefore, this investigation aims to report a new high-throughput assay approach based on NMPCR technology followed by automatic capillary electrophoresis (CE) to simultaneously detect 40 genotypes of HPV. This methodology allows for the detection of multiple infections, demonstrating its performance in epidemiological studies.
To assess the effectiveness of NMPCR-CE for HPV-type detection, we evaluated its sensitivity and specificity in comparison to both conventional cytopathological analysis and the Hybrid Capture 2 assay (HC2). An extensive epidemiological study was conducted in a population of Brazilian women undergoing routine gynecological follow-up. The results and their implications for diagnosis and clinical follow-up are discussed.

2. Materials and Methods

The present study was designed to report a new molecular assay based on a one-tube nested multiplex PCR (NMPCR) that simultaneously detects 40 HPV genotypes, which was compared to the Hybrid Capture 2 and cytopathological exams. Moreover, we performed a molecular epidemiological study of the Brazilian female population to validate the new HPV NMPCR assay (Figure 1).

2.1. Patient Accrual and Sample Collection

The design of the HPV screening study is depicted in Figure 2. In the first phase, we evaluated the performance of the novel assay in comparison to the commercially available Hybrid Capture 2 (HC2) assay. For this purpose, 40 patients were consecutively recruited during routine gynecological examinations, including cytopathological tests, in São Luís, Maranhão State, Brazil, a region with high HPV endemicity. The study was conducted in accordance with the Declaration of Helsinki, it was approved by the Research Ethics Committee of the Federal University of Maranhão (3060/2008-47), and all participants provided informed consent, with their identities remaining anonymous. The analyses followed a double-blind protocol, with samples independently tested using NMPCR and HC2 in two separate laboratories: BioGenetics (Uberlândia, MG, Brazil) and Digene (São Paulo, SP, Brazil). The mean age of the patients was 37.5 years old (ranging from 18 to 81 years of age). Clinical data were obtained from routine gynecological evaluation by Papanicolaou (Pap smears) testing (analysis of medical records) and the collection of cervical samples for detection of HPV genomic DNA.
In the second phase, a comprehensive epidemiological study was conducted across the Brazilian female population for HPV screening, encompassing all the states of Brazil. This large-scale study included 5233 cervical swab samples collected during routine gynecological exams from various clinics across Brazil between 2009 and 2017. The analyses were performed at the BioGenetics Diagnósticos Laboratory (Uberlândia, Minas Gerais, Brazil) using NMPCR for the detection and genotyping of 40 HPV subtypes. Genital specimens were collected using endocervical and ectocervical swabs placed in sterile tubes containing 1 mL of lysis buffer (10 mM Tris-HCl, 2 mM EDTA, and 400 mM NaCl), and maintained at room temperature.
Among this cohort, 170 patients from Uberlândia, MG (Mid-Central Brazil) aged 25 years and older were specifically monitored for cytological abnormalities, including cervical intraepithelial neoplasia (CIN). All participants provided informed consent. The state of Minas Gerais serves as a representative sample of the Brazilian population due to its rapid growth and influx of migrants from across the country. This study was also conducted in accordance with the Declaration of Helsinki, and it was approved by the Research Ethics Committee of the Federal University of Uberlândia (CEP/UFU 013/1999).

2.2. DNA Extraction from Cervical Samples

In the first phase of the study (São Luis Cohort, N = 40 patients), genital samples were placed in a 500 µL lysis buffer (400 mM NaCl, 50 mM EDTA, and 25 mM Tris-HCl, pH 8.0), vigorously agitated, and then transferred to a new microtube for DNA extraction. Proteinase K (10 µL) and 10% of sodium dodecyl sulfate (SDS) (10 µL) were added for protein degradation. Microtubes were incubated in a water bath at 60 °C for a minimum of 2 h. After incubation, a saturated NaCl buffer was added to 1/3 of the sample volume, and tubes were further incubated for 10 min at −20 °C. Samples were then centrifuged at 11,000 rpm for 15 min to precipitate cell debris. The liquid supernatant was transferred into a new tube in which a 2X volume of absolute ethanol was added for DNA precipitation that was centrifuged at 11,000 rpm for 15 min. The precipitated DNA was washed with 70% ethanol, resuspended in about 20 µL deionized water, and stored at 4 °C for subsequent PCR. In the second phase, genomic DNA extraction for the cohort involved in the epidemiological study was also manually conducted between 2009 and 2017, using cell samples collected via cervical swabs and applying the salting-out technique. [28].

2.3. Outer Multiplex PCR Conditions

For the first round of amplification (the outer PCR reaction), one consensus MY09 primer, as previously reported [12], was used. Additionally, nine newly designed degenerate primers (four MY09BG and five MY11BG) were introduced as a modified version of the original MY09/11 primer system [12] to cover the sequences of forty HPV genotypes. The constitutive β-globin (BG; GenBank Entrez U01317) gene was employed as an internal positive control for the reaction and to assess the efficiency of DNA extraction (Table 1).
The PCR mixture was performed in a final volume of 30 µL, containing 7 µL of DNA (5 ng/µL), 50 mM of KCl, 10 mM of Tris-HCl (pH 8.3), 1.5 mM of MgCl2, 120 µM of final concentration of deoxynucleoside triphosphate (dNTP), 1.5 U of AmpliTaq Gold DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA), 0.675 pmol of each MY09/MY11 primer, and 2 pmol of each BG1 and BG2 primers. The reaction was incubated for 40 cycles at 94 °C for 1 min, 50 °C for 1 min, 72 °C for 2 min, and a final extension cycle at 72 °C for 5 min.

2.4. Nested-Multiplex PCR (NMPCR) Conditions

In the second reaction, 40 specific primers labeled with fluorophores were arranged in a cocktail multiplex PCR. They were designed to identify the high-risk (16, 18, 26, 30, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, and 82), medium-risk (54, 55, 61, 62, 64, 71, 72, 74, 81, 83, and 84), and low-risk genotypes (06, 11, 42, 43, 44, and 57). The BG2 with BG3 primers for the constitutive β-globin gene were used. All primer sequences used are presented in Table 2.
The second PCR amplification had a final volume of 15 µL: 50 mM of KCl, 10 mM of Tris-HCl (pH 8.3), 1.5 mM of MgCl2 enhancer (1.5X), 60 µM of dNTPs, 1.0 U of AmpliTaq Gold DNA Polymerase (Thermo Fisher Scientific), 0.5 pmol of each HPV specific primer, and 0.3 pmol of control primers (BG2 and BG3). Two microliters of the MY11/09 PCR products were used as template for nested PCR amplification. The reaction was incubated for 36 cycles at 95 °C for 2 min, 56 °C for 1 min, 72 °C for 40 s, and a final extension cycle at 72 °C for 5 min. Additionally, we performed serial dilutions to determine the minimum concentration capable of detecting the viral subtypes, ranging from 10−3 to 10−6 µg/µL, with successful detection even at concentrations as low as 10−6 µg/µL.

2.5. Capillary Electrophoresis (CE)

The amplified product from NMPCR was diluted 200X, and 1 µL was submitted to capillary electrophoresis (MegaBase 1000, Amersham Pharmacia Biotech, Piscataway, NJ, USA) using the internal standard molecular weight ETRox550 (GE Healthcare, Chicago, IL, USA) for samples analysis (Figure 1). For the electropherogram analysis, we have built a new peak filter with the software Fragment Profiler 1.2 (GE HeathCare) with three fluorescein-labeled probes: FAM (6-carboxyfluorescein), HEX (5′-hexachlorofluorescein phosphoramidite), or TAMRA (6-carboxytetramethylrhodamine) (Table 2). The results were classified as positive in the presence of amplification for one (single infection) or more HPV viral types (multiple infections), generating 74–338 bp fragments, with the presence of the internal control amplification (β-globin gene-BG, 366 bp). The results were considered negative when only the β-globin (BG) gene was amplified and indeterminate when no amplification was observed for either HPV or the BG control.

2.6. Hybrid Capture 2 Assay (CH2)

HPV DNA detection was performed by the commercially available Hybrid Capture 2 assay (HC2, Qiagen) at Digene (São Paulo, Brazil). The HC2 assay is a nucleic acid hybridization assay with signal amplification that utilizes microplate chemiluminescent detection. Samples collections were performed in an appropriate tube provided in the HC2 kit. All scrapes were analyzed for the presence of low-risk HPV types 6, 11, 42, 43, and 44 and for the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The HC2 positive results were categorized as HPV-A (Low-Risk), HPV-B (High-Risk), or both HPV-A/-B genotypes.

2.7. Statistical Analysis

Statistical analyses, tables, and graphs were produced using BioEstat (version 5.3) and GraphPad Prism (version 5) software. The detection of high-grade CIN2+ and CIN3+ lesions were assessed using sensitivity and specificity parameters. The detection of HPV in all CIN+ lesions were also determined in both São Luís (Maranhão) and Uberlândia (Minas Gerais), Brazil.

3. Results

3.1. The Nested-Multiplex PCR and Diagnostic Parameters

The length of the amplicons generated by the first amplification with MY09/11 degenerated primers was 450-bp (Figure 3A). The β-globin gene detection rate was ≥90%, validating the DNA extraction method for HPV detection (Figure 3B). The HPV detection and genotyping by NMPCR were confirmed in agarose gel electrophoresis by selecting amplified samples with single infections ordered by size (Figure 3C) and also in multiple infections (Figure 3D). DNA amplicons from single and multiple infections from 40 randomly selected women representing all genotypes were excised from the gel, purified, and their sequences were confirmed by DNA sequencing. Additionally, the single-tube NMPCR was able to detect differences in viral load in double or multiple infections (Figure 3E) when serial dilutions were applied to samples prior to amplification, indicating that a decreased viral load of samples with multiple infections may result in detection failure, either by using conventional PCR or by the HC2 assay.
HPV detection using NMPCR in patients from São Luís-MA (N = 40) was approximately twice as high as that obtained through HC2 and cytopathology assays (Table 3), with positivity rates of 75%, 30%, and 40%, respectively. Among the infected patients, at least one high-risk HPV genotype was identified in 86.7% (26/30) of cases. Additionally, 83.3% (25/30) of the women had multiple infections. Remarkably, 71.4% (20/28) of the patients who tested negative by the HC2 assay were found to be positive by NMPCR, with 85.0% of these harboring high-risk HPV and 47.0% already exhibiting cytological lesions. Conversely, among the 10 patients who tested negative by NMPCR, only 2 (20%) were positive by HC2, and, notably, no cytological lesions were observed in these patients. Detailed comparisons of the three assays for each patient are provided in Supplementary Table S1.

3.2. Epidemiological Data

The Brazilian female population presented an HPV prevalence of 59.0%, among whom 58.0% had multiple infections and, among them, 60% harbored hrHPV genotypes. The frequency of HPV genotypes are presented in Table 4, which shows higher prevalence of single infections by HPV-6 (15.1%), followed by hrHPV-53 (7.1%), 31 (5.2%), and 16 (4.2%); however, among those with multiple infections, in addition to HPV-6 being the most prevalent (27.5%), HPV types 52, 54, 53, 42, 61, 51, and 16 were present in 13.4% to 18.3% of the cases, suggesting that the majority of cases have multiple infections, including a mixture of low- and high-risk genotypes. The supplementary Table S2 shows the HPV DNA prevalence in female genitals from other studies.
We emphasize that 170 Papanicolaou samples from Uberlândia (Minas Gerais, Brazil) were clinically monitored for CIN+ lesions: 54.1% did not show cellular abnormalities, 21.2% were CIN1+, 10% were CIN2+, 13.5% were CIN3+, and 1.2% were classified as having adenocarcinoma. In addition, among 99 NMPCR negative samples, 15% showed cell abnormalities that were probably due to causes other than HPV infection. Considering CIN2+ and CIN3+ lesions only (40 out of 170), both the sensitivity and specificity of the NMPCR assay were 100%. Considering all CIN+ lesions and adenocarcinoma from both cities (São Luís-MA and Uberlandia-MG), the sensitivity and specificity were 97.5% and 100%, respectively. It is important to note that among three negative cases, two with CIN1+ lesions and one with adenocarcinoma, were also negative for HC2. Interestingly, among 80 specimens with CIN+ lesions from Uberlândia, we have also shown that as the disease progressed to severe lesions, single infections tended to predominate with hrHPV genotypes, culminating in adenocarcinoma with 1 virus or none at all (Figure 4), probably due to important genetic changes that may have led to the loss of cell architecture and physiological functions. Our study has also revealed important epidemiological data regarding the infection related to a woman’s age, i.e., there was a higher incidence of HPV infections in women between 19 and 30 years old and between 56 and 85 years old, mainly those with multiple infections.

4. Discussion

This study reports a novel high-throughput nested-multiplex PCR assay that uses a highly sensitive and specific broad-spectrum HPV DNA amplification on a single tube that allows the simultaneous detection of 40 common genital HPV genotypes. The results present significant epidemiological data that may change public health programs and may become an important molecular tool to monitor populations before and after HPV vaccination.
The viral genome contains highly conserved regions, for which several consensus PCR primer sets have been designed aiming for general HPV DNA detection, such as MY09/MY11 [16], GP5+/6+ [20,29], and SPF1/2 [30], resulting in distinct amplification of HPV DNA. However, the MY09/MY11 system has shown not only greater sensitivity than the other systems but also allows the identification of specific HPV genotypes.
The nested-multiplex PCR assay (NMPCR) uses 1 of the original MY09/11 primer sets for the first PCR reaction with 9 additional degenerated primers to amplify all 40 genital HPV genotypes. The nested (second-round) specific amplification reaction was performed simultaneously in a single tube with 40 primer pairs with great efficiency and sensitivity, and it was designed to separate each virus genotype based on different amplicon sizes. Amplicons were separated into three sets of fluorophores to facilitate detection (Figure 1; Table 1 and Table 2). It is important to emphasize that the degeneration of primers in the first round of amplification was necessary to cover all the genomic variations within and among genotypes.
The technology proved to be highly precise and specific and capable of being performed even with small sample quantities. Although nested reactions may present the possibility of cross-contamination due to excess handling, we have observed no contamination. Our handling process of the nested reactions used as a general rule the individual manipulation of each sample at a time to prevent first-reaction spray and carry over. In order to demonstrate that reactions were not contaminated, random samples with multiple infections were individually tested with specific primers for those viruses previously detected by automatic capillary electrophoresis. All results were confirmed by agarose gel electrophoresis in separate reactions for each virus.
Our study involving 5223 patients consecutively recruited in routine gynecological examinations showed an HPV prevalence of 59.0%. In 2020, Wendland et al. [31] conducted an epidemiological study of HPV in Brazil with 5268 women and 1120 men who were sexually active and unvaccinated, aged between 16 and 25 years. The authors used a linear array (Roche) as a genotyping method, which detects 37 types of HPV, although only 13 high-risk genotypes, demonstrating a prevalence of HPV infection in 54.6% of the female population, corroborating our data. However, HPV prevalence varies across populations and is shaped by differences in diagnostic methods, sampling sites, population behaviors, cultural practices, and socioeconomic development indices.
Our new assay identified viral genotypes whose prevalence had not been investigated before, and, most importantly, it showed an extensive epidemiological profile of multiple and single infections not previously explored. A study carried out in the Northeast of Brazil with 250 women found 48% with HPV infections, with the most common type being HPV16 [32]. A large epidemiological study performed in Rio de Janeiro with 5833 women [33] detected the presence of HPV through the HC2 system with a positivity of 44.9%, with 25.5% related to high-risk genotypes. None of those studies were carried out by consecutive sampling without bias, which means that, in these cases, most of the women could be considered at risk or be suspected of having an HPV infection. It is important to note that clinicians at laboratories used for HPV detection or cancer screening usually refer women in Brazil when they present altered cytology or clinical signs. Comparisons across studies are presented in Supplementary Table S2 [31,32,33,34,35,36,37,38,39,40,41,42].
Our large Brazilian epidemiological study revealed a predominance of multiple infections characterized by a mixture of low- and high-risk viruses at varying titers. As expected, an increased detection of HPV genotypes correlates with a higher prevalence. This suggests that undetected genotypes may become more significant over time, as type-specific vaccines might favor viral selection and amplification. In addition, detecting multiple infections is crucial, as patients with co-infections are at a higher risk of treatment failure [43]. In our study, the presence of low-titer, high-risk viruses alongside high-titer, low-risk viruses may have impacted the HC2 assay results. This is likely due to the HC2 assay’s use of a probe pool representing both low- and high-risk genotypes, where competition between probes could affect the accuracy of the detection. Therefore, the method presented in this study offers a robust approach for epidemiological surveillance, facilitating precise monitoring and timely interventions that promote better clinical outcomes.
Comparisons among NMPCR, HC2, and cytopathology assays also demonstrated false negative results for both HC2 and cytopathology, with a 50% and 40% rate of misdiagnosis, respectively, which may significantly impact public health programs and disease management, consequently hampering the measures used to prevent and control HPV infection by allowing the continuity of the transmission chain. Note that the discrepancy between genotyping and cytopathology can be attributed to frequent false-negative smears [35], which may be due to inadequate sampling or misinterpretation of the results [44]. On the other hand, false-positive Pap smears may be related to other cervical diseases unrelated to HPV [45,46,47]. Furthermore, women who have reached post-menopause or with more than 70 years of age are likely to present genital atrophy that can lead to increased inaccurate results [48,49]. Additionally, the HC2 assay not only has a limitation in identifying genotypes but also exhibits cross-reactivity between low-risk and high-risk groups.
Recent molecular approaches have emerged for clinical practice with high sensitivity and specificity, which are characterized by HPV detection and genotyping based on signal amplification methods (hybridization techniques in liquid phase) or target amplification methods (PCR amplification) with coverage varying from 15 to 34 HPV genotypes [26,50]. Our novel NMPCR tool coupled with capillary electrophoresis covers 40 genotypes, and in addition to its utility in HPV detection and genotyping, it is also able to determine the genotypic dominance in multiple infections, demonstrating that co-infections with prevalent low-risk genotypes may mask the detection of high-risk ones, especially when conventional PCR or hybridization assays are used. Another important finding in this study was the decreased number of multiple infections during disease progression, resulting in the occurrence of a single high-risk virus or complete viral loss in the adenocarcinoma stage. It is important to emphasize that during cancer development, modulation of transcription factors may inhibit viral replication, leading to a reduced number of viral copies in the cell, which may become undetectable by molecular techniques [51].
This study has certain limitations. Not all HPV-positive women were referred for colposcopy due to the wide geographic distribution of the clinics involved in sample collection across the country. Comprehensive cervical sampling followed by colposcopy was conducted in two cities, São Luís (MA) and Uberlândia (MG); thus, the specificity of the NMPCR assay may have been affected by this limited scope of follow-up.

5. Conclusions

The novel nested-multiplex PCR method described in this study represents a highly promising and robust tool for HPV diagnostics, with applications extending beyond population screening to the clinical follow-up of patients. Its capability to simultaneously detect, genotype, and assess viral dominance within a single tube has yielded valuable new epidemiological data. This new method may significantly impact clinical management and treatment strategies as well as influence cervical cancer statistics by facilitating the detection of subclinical infections and enabling the effective monitoring of populations, particularly in endemic regions.

6. Patents

Patent applications: BR1020170046150, filed in 8 March 2017 and WO/2018/161140, filed on 8 March 2018.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms12112326/s1, Table S1: Comparative analysis of Nested Multiplex PCR (NMPCR), Cytopathology, and Hybrid Capture II (HC2) assays from genital swabs collected from 40 consecutively recruited women during routine HPV infection monitoring at a gynecology clinic in São Luís, MA, Northeast Brazil. Table S2: Reported prevalence of HPV DNA in female genital samples from epidemiological studies. Reference [52] is cited in the Supplementary Materials

Author Contributions

Conceptualization, L.R.G. and S.R.P.; sample collection, B.F.M.C., J.S.J. and M.S.A.d.A.; methodology, L.R.G., J.S.J. and A.F.N.; formal analysis, L.R.G. and S.R.P.; writing—original draft preparation, B.F.M.C., L.R.G., and S.R.P.; writing—review and editing, L.R.G., S.R.P. and M.I.S.L.; project administration, L.R.G.; funding acquisition, L.R.G. and S.R.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Fundação de Amparo à Pesquisa do Estado Minas Gerais (FAPEMIG; grant number CBB-APQ-03613-17), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/INCT Teranóstica e Nanobiotecnologia/TeraNano; grant number CNPq 403193/2022-2), and BioGenetics Laboratories.

Data Availability Statement

The epidemiological data are not available as they consist of confidential patient test results from BioGenetics Diagnósticos Laboratories. Other original contributions presented in the study are included in the article and Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare that the nested-multiplex PCR technology for HPV detection and genotyping is included in joint patent application PCT/BR2018/050062, filed on 8 March 2018, by the Federal University of Uberlândia, FAPEMIG (Brazil), and BioGenetics Diagnósticos Laboratories. Author Juliana São Julião was employed by BioGenetics Tecnologia Molecular Ltda. The first author, L.R.G. (in memoriam), was a founding partner of the Biogenetics Diagnostics Laboratory. The remaining authors report no commercial or financial relationships that could be perceived as potential conflicts of interest. The funders had no role in study design, data collection, analysis, interpretation, manuscript preparation, or the decision to publish.

References

  1. Cohen, P.A.; Jhingran, A.; Oaknin, A.; Denny, L. Cervical cancer. Lancet 2019, 393, 169–182. [Google Scholar] [CrossRef] [PubMed]
  2. Macedo, J.; Silva, E.; Nogueira, L.; Coelho, R.; da Silva, J.; dos Santos, A.; Teixeira-Júnior, A.A.; Belfort, M.; Silva, G.; Khayat, A.; et al. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer. Mol. Carcinog. 2020, 59, 604–617. [Google Scholar] [CrossRef] [PubMed]
  3. Serrano, B.; Brotons, M.; Bosch, F.X.; Bruni, L. Epidemiology and burden of HPV-related disease. Best. Pract. Res. Clin. Obstet. Gynaecol. 2018, 47, 14–26. [Google Scholar] [CrossRef] [PubMed]
  4. Allison, D.B.; Maleki, Z. HPV-related head and neck squamous cell carcinoma: An update and review. J. Am. Soc. Cytopathol. 2016, 5, 203–215. [Google Scholar] [CrossRef] [PubMed]
  5. WHO. Cervix Uteri—The Global Cancer Observatory—Globocan 2022, World Health Organization. International Agency for Research on Cancer. Available online: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf (accessed on 1 February 2024).
  6. Forman, D.; de Martel, C.; Lacey, C.J.; Soerjomataram, I.; Lortet-Tieulent, J.; Bruni, L.; Vignat, J.; Ferlay, J.; Bray, F.; Plummer, M.; et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30 (Suppl. S5), F12–F23. [Google Scholar] [CrossRef]
  7. Canfell, K. Towards the global elimination of cervical cancer. Papillomavirus Res. 2019, 8, 100170. [Google Scholar] [CrossRef]
  8. Denny, L. Control of cancer of the cervix in low- and middle-income countries. Ann. Surg. Oncol. 2015, 22, 728–733. [Google Scholar] [CrossRef]
  9. Graham, S.V. The human papillomavirus replication cycle, and its links to cancer progression: A comprehensive review. Clin. Sci. 2017, 131, 2201–2221. [Google Scholar] [CrossRef]
  10. Sanchez-Vargas, L.O.; Diaz-Hernandez, C.; Martinez-Martinez, A. Detection of Human Papilloma Virus (HPV) in oral mucosa of women with cervical lesions and their relation to oral sex practices. Infect. Agent. Cancer 2010, 5, 25. [Google Scholar] [CrossRef]
  11. de Villiers, E.M. Human pathogenic papillomavirus types: An update. Curr. Topics Microbiol. Immunol. 1994, 186, 1–12. [Google Scholar] [CrossRef]
  12. Burd, E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003, 16, 1–17. [Google Scholar] [CrossRef] [PubMed]
  13. Ho, C.M.; Yang, S.S.; Chien, T.Y.; Huang, S.H.; Jeng, C.J.; Chang, S.F. Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol. Oncol. 2005, 99, 615–621. [Google Scholar] [CrossRef] [PubMed]
  14. Harden, M.E.; Munger, K. Human papillomavirus molecular biology. Mutat. Res./Rev. Mutat. Res. 2017, 772, 3–12. [Google Scholar] [CrossRef] [PubMed]
  15. Pastrana, D.V.; Peretti, A.; Welch, N.L.; Borgogna, C.; Olivero, C.; Badolato, R.; Notarangelo, L.D.; Gariglio, M.; FitzGerald, P.C.; McIntosh, C.E.; et al. Metagenomic discovery of 83 new human papillomavirus types in patients with immunodeficiency. mSphere 2018, 3, e00645-18. [Google Scholar] [CrossRef] [PubMed]
  16. Manos, M.M.; Ting, Y.; Wright, D.K.; Lewis, A.J.; Broker, T.R.; Wolinski, S.M. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989, 7, 209–214. [Google Scholar]
  17. Manos, M.M.; Gluzman, Y. Genetic and biochemical analysis of transformation-competent, replication-defective simian virus 40 large T antigen mutants. J. Virol. 1985, 53, 120–127. [Google Scholar] [CrossRef]
  18. Snijders, P.J.; van den Brule, A.J.; Schrijnemakers, H.F.; Snow, G.; Meijer, C.J.; Walboomers, J.M. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J. Gen. Virol. 1990, 71 Pt 1, 173–181. [Google Scholar] [CrossRef]
  19. Chouhy, D.; Gorosito, M.; Sanchez, A.; Sánchez, A.; Serra, E.C.; Bergero, A.; Fernandez Bussy, R.; Giri, A.A. New generic primer system targeting mucosal/genital and cutaneous human papillomaviruses leads to the characterization of HPV 115, a novel Beta-papillomavirus species 3. Virology 2010, 397, 205–216. [Google Scholar] [CrossRef]
  20. Gravitt, P.E.; Peyton, C.L.; Alessi, T.Q.; Wheeler, C.M.; Coutlée, F.; Hildesheim, A.; Schiffman, M.H.; Scott, D.R.; Apple, R.J. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 2000, 38, 357–361. [Google Scholar] [CrossRef]
  21. Soderlund-Strand, A.; Dillner, J.; Carlson, J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin. Chem. 2008, 54, 86–92. [Google Scholar] [CrossRef]
  22. Cassani, B.; Soldano, G.; Finocchiaro, D.; Conti, S.; Bulfamante, A.; Lemorini, G.; Bulfamante, G. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples. Pathologica 2018, 110, 294–301. [Google Scholar] [PubMed]
  23. Leal, S.M., Jr.; Gulley, M.L. Current and Emerging Molecular Tests for Human Papillomavirus-Related Neoplasia in the Genomic Era. J. Mol. Diagn. 2017, 19, 366–377. [Google Scholar] [CrossRef] [PubMed]
  24. Chamberlain, J.S.; Gibbs, R.A.; Ranier, J.E.; Nguyen, P.N.; Caskey, C.T. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988, 16, 11141–11156. [Google Scholar] [CrossRef] [PubMed]
  25. Kuo, Y.B.; Li, Y.S.; Chan, E.C. Rapid identification of HPV 16 and 18 by multiplex nested PCR-immunochromatographic test. J. Virol. Methods 2015, 212, 8–11. [Google Scholar] [CrossRef] [PubMed]
  26. Mudhigeti, N.; Kalawat, U.; Hulikal, N.; Racherla, R.G. E6-E7 based nested multiplex PCR assay for genital HPV detection and simultaneous typing of 15 high and low-risk HPV types. Indian. J. Med. Microbiol. 2022, 40, 18–23. [Google Scholar] [CrossRef]
  27. US Preventive Services Task Force; Curry, S.J.; Krist, A.H.; Owens, D.K.; Barry, M.J.; Caughey, A.B.; Davidson, K.W.; Doubeni, C.A.; Epling, J.W., Jr.; Kemper, A.R.; et al. Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement. JAMA 2018, 320, 674–686. [Google Scholar] [CrossRef]
  28. Miller, S.A.; Dykes, D.D.; Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16, 1215. [Google Scholar] [CrossRef]
  29. de Roda Husman, A.M.; Walboomers, J.M.; van den Brule, A.J.; Meijer, C.J.; Snijders, P.J. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 1995, 76 Pt 4, 1057–1062. [Google Scholar] [CrossRef]
  30. van Muyden, R.C.; ter Harmsel, B.W.; Smedts, F.M.; Hermans, J.; Kuijpers, J.C.; Raikhlin, N.T.; Petrov, S.; Lebedev, A.; Ramaekers, F.C.; Trimbos, J.B.; et al. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: A prognostic study. Cancer 1999, 85, 2011–2016. [Google Scholar] [CrossRef]
  31. Wendland, E.M.; Villa, L.L.; Unger, E.R.; Domingues, C.M.; Benzaken, A.S.; POP-Brazil Study Group. Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study. Sci. Rep. 2020, 10, 4920. [Google Scholar] [CrossRef]
  32. Fernandes, J.V.; de Vasconcellos Meissner, R.; de Carvalho, M.G.; Fernandes, T.A.; de Azevedo, P.R.; Villa, L.L. Prevalence of HPV infection by cervical cytologic status in Brazil. Int. J. Gynaecol. Obstet. 2009, 105, 21–24. [Google Scholar] [CrossRef]
  33. Carestiato, F.N.; Silva, K.C.; Dimetz, T.; Oliveira, L.H.; Cavalcanti, S.M. Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz. J. Infec Dis. 2006, 10, 331–336. [Google Scholar] [CrossRef] [PubMed]
  34. Basiletti, J.A.; Valls, J.; Poklépovich, T.; Fellner, M.D.; Rol, M.; Alonso, R.; Correa, R.M.; Colucci, M.C.; Rodríguez de la Peña, M.; Falabella, P.G.; et al. Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections. PLoS ONE 2022, 17, e0278117. [Google Scholar] [CrossRef] [PubMed]
  35. Zhao, X.; Wu, Q.; Wang, X.; Fu, Y.; Zhang, X.; Tian, X.; Cheng, B.; Lu, B.; Yu, X.; Lan, S.; et al. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: A cross-sectional study in 10,669 Chinese women. Clin. Microbiol. Infect. 2018, 24, 1322–1327. [Google Scholar] [CrossRef]
  36. Ramas, V.; Mirazo, S.; Bonilla, S.; Mendoza, L.; Lago, O.; Basiletti, J.; González, J.; Picconi, M.A.; Arbiza, J. Human papillomavirus genotypes distribution in cervical samples from Uruguayan women. J. Med. Virol. 2013, 85, 845–851. [Google Scholar] [CrossRef] [PubMed]
  37. Amaro-Filho, S.M.; Golub, J.E.; Nuovo, G.J.; Cunha, C.B.; Levi, J.E.; Villa, L.L.; Andrade, C.V.; Russomano, F.B.; Tristão, A.; Pires, A.; et al. A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PloS ONE 2013, 8, e57810. [Google Scholar] [CrossRef]
  38. Aruhuri, B.; Tarivonda, L.; Tenet, V.; Sinha, R.; Snijders, P.J.; Clifford, G.; Pang, J.; McAdam, M.; Meijer, C.J.; Frazer, I.H.; et al. Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev. Res. 2012, 5, 746–753. [Google Scholar] [CrossRef]
  39. Kondo, K.; Uenoyama, A.; Kitagawa, R.; Tsunoda, H.; Kusumoto-Matsuo, R.; Mori, S.; Ishii, Y.; Takeuchi, T.; Kanda, T.; Kukimoto, I. Genotype distribution of human papillomaviruses in Japanese women with abnormal cervical cytology. Open Virol. J. 2012, 6, 277–283. [Google Scholar] [CrossRef]
  40. Martin, P.; Kilany, L.; Garcia, D.; López-Garcia, A.M.; Martín-Azaña, M.J.; Abraira, V.; Bellas, C. Human papillomavirus genotype distribution in Madrid and correlation with cytological data. BMC Infect. Dis. 2011, 11, 316. [Google Scholar] [CrossRef]
  41. Dunne, E.F.; Unger, E.R.; Sternberg, M.; McQuillan, G.; Swan, D.C.; Patel, S.S.; Markowitz, L.E. Prevalence of HPV infection among females in the United States. JAMA 2007, 297, 813–819. [Google Scholar] [CrossRef]
  42. Sotlar, K.; Diemer, D.; Dethleffs, A.; Hack, Y.; Stubner, A.; Vollmer, N.; Menton, S.; Menton, M.; Dietz, K.; Wallwiener, D.; et al. Detection and typing of human papillomavirus by E6 nested multiplex PCR. J. Clin. Microbiol. 2004, 42, 3176–3184. [Google Scholar] [CrossRef] [PubMed]
  43. Munagala, R.; Donà, M.G.; Rai, S.N.; Jenson, A.B.; Bala, N.; Ghim, S.J.; Gupta, R.C. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int. J. Oncol. 2009, 34, 263–271. [Google Scholar] [PubMed]
  44. Sana, D.E.; Mayrink de Miranda, P.; Pitol, B.C.; Moran, M.S.; Silva, N.N.; Guerreiro da Silva, I.D.; de Cássia Stocco, R.; Beçak, W.; Lima, A.A.; Carneiro, C.M. Morphometric evaluation and nonclassical criteria for the diagnosis of HPV infection and cytological atypia in cervical samples. Diagn. Cytopathol. 2013, 41, 785–792. [Google Scholar] [CrossRef]
  45. Jin, X.W.; Sikon, A.; Yen-Lieberman, B. Cervical cancer screening: Less testing, smarter testing. Clevel. Clin. J. Med. 2011, 78, 737–747. [Google Scholar] [CrossRef]
  46. Chin, P.S.; Chia, Y.N.; Lim, Y.K.; Yam, K.L. Diagnosis and management of Mullerian adenosarcoma of the uterine cervix. Int. J. Gynaecol. Obstet. 2013, 121, 229–232. [Google Scholar] [CrossRef]
  47. Long, M.E.; Dwarica, D.S.; Kastner, T.M.; Gallenberg, M.M.; Chantigian, P.D.; Marnach, M.L.; Weaver, A.L.; Casey, P.M. Comparison of dysplastic and benign endocervical polyps. J. Low. Genit. Tract. Dis. 2013, 17, 142–146. [Google Scholar] [CrossRef]
  48. Sawaya, G.F.; Grady, D.; Kerlikowske, K.; Valleur, J.L.; Barnabei, V.M.; Bass, K.; Snyder, T.E.; Pickar, J.H.; Agarwal, S.K.; Mandelblatt, J. The positive predictive value of cervical smears in previously screened postmenopausal women: The Heart and Estrogen/progestin Replacement Study (HERS). Ann. Intern. Med. 2000, 133, 942–950. [Google Scholar] [CrossRef] [PubMed]
  49. Rositch, A.F.; Silver, M.I.; Burke, A.; Viscidi, R.; Chang, K.; Duke, C.M.; Shen, W.; Gravitt, P.E. The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women. J. Low. Genit. tract Dis. 2013, 17, 38–47. [Google Scholar] [CrossRef] [PubMed]
  50. Aissam, E.A.; Jaddi, H.; Ennaji, M.M.; Mzibri, M.E.L. Recent Advances in Human Papillomavirus Detection and Genotyping. Br. Microbiol. Res. J. 2016, 11, 1–22. [Google Scholar] [CrossRef]
  51. Ekeowa-Anderson, A.L.; Purdie, K.J.; Gibbon, K.; Byrne, C.R.; Arbeit, J.M.; Harwood, C.A.; O’Shaughnessy, R.F. AKT1 loss correlates with episomal HPV16 in vulval intraepithelial neoplasia. PLoS ONE 2012, 7, e38608. [Google Scholar] [CrossRef]
  52. Almonte, M.; Murillo, R.; Sánchez, G.I.; González, P.; Ferrera, A.; Picconi, M.A.; Wiesner, C.; Cruz-Valdez, A.; Lazcano-Ponce, E.; Jerónimo, J.; et al. Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: The ESTAMPA screening study protocol. BMJ Open 2020, 10, e035796. [Google Scholar] [CrossRef] [PubMed]
Microorganisms 12 02326 g001
Figure 1. Schematic representation of the nested-multiplex polymerase chain reaction (NMPCR) for HPV detection and genotyping. It demonstrates a sample with double infection with HPV16 and HPV39, using β-globin as a reaction control. Although the peak intensities of both HPV genotypes are similar in this case, they may differ based on differential virus titers, indicating virus dominance for those with high intensity peaks.
Figure 1. Schematic representation of the nested-multiplex polymerase chain reaction (NMPCR) for HPV detection and genotyping. It demonstrates a sample with double infection with HPV16 and HPV39, using β-globin as a reaction control. Although the peak intensities of both HPV genotypes are similar in this case, they may differ based on differential virus titers, indicating virus dominance for those with high intensity peaks.
Microorganisms 12 02326 g001
Microorganisms 12 02326 g002
Figure 2. Study design applied to the Brazilian population (N = 5273).
Figure 2. Study design applied to the Brazilian population (N = 5273).
Microorganisms 12 02326 g002
Microorganisms 12 02326 g003
Figure 3. HPV genotypes of random samples and controls amplified by NMPCR as detected in agarose gel electrophoresis. (A): Example of first-round amplification (outer-PCR reaction) using 10 degenerated primers, generating 450-bp amplicons. (B): Examples of first-round amplification of the internal control of PCR reaction (β-globin gene), generating fragments of 366-bp. (C): Amplification of 11 single HPV types ordered by size. (D): Detection of single and multiple HPV infections in cervical samples. (E): Viral dominance detected by sample dilution of double HPV infections amplified by NMPCR; the left panel shows double infection with HPV16/35 with similar titers, and the right panel shows double infection with HPV35/61 with significant differences in titers (10−3 µg/µL to 10−6 µg/µL), with dominance of HPV35. Viral types are represented below in (C,D). Abbreviations: C, negative control; β-globin gene; M1, 100 bp molecular marker; M2, 50 bp molecular marker.
Figure 3. HPV genotypes of random samples and controls amplified by NMPCR as detected in agarose gel electrophoresis. (A): Example of first-round amplification (outer-PCR reaction) using 10 degenerated primers, generating 450-bp amplicons. (B): Examples of first-round amplification of the internal control of PCR reaction (β-globin gene), generating fragments of 366-bp. (C): Amplification of 11 single HPV types ordered by size. (D): Detection of single and multiple HPV infections in cervical samples. (E): Viral dominance detected by sample dilution of double HPV infections amplified by NMPCR; the left panel shows double infection with HPV16/35 with similar titers, and the right panel shows double infection with HPV35/61 with significant differences in titers (10−3 µg/µL to 10−6 µg/µL), with dominance of HPV35. Viral types are represented below in (C,D). Abbreviations: C, negative control; β-globin gene; M1, 100 bp molecular marker; M2, 50 bp molecular marker.
Microorganisms 12 02326 g003
Microorganisms 12 02326 g004
Figure 4. Predominance of hrHPV in single and multiple infections according to disease progress from cervical intraepithelial neoplasia (CIN 1, CIN2, and CIN3) to adenocarcinoma.
Figure 4. Predominance of hrHPV in single and multiple infections according to disease progress from cervical intraepithelial neoplasia (CIN 1, CIN2, and CIN3) to adenocarcinoma.
Microorganisms 12 02326 g004
Table 1. Sequences of consensus and degenerate primers used in the outer PCR for the general amplification of all HPV genotypes along with β-globin (BG) PCR primers as a human constitutive gene internal control.
Table 1. Sequences of consensus and degenerate primers used in the outer PCR for the general amplification of all HPV genotypes along with β-globin (BG) PCR primers as a human constitutive gene internal control.
TypeIDSequences *SourceAmplicon Size (bp)
ConsensusMY09CGT CCM AAR GGA HAC TGA TC[11]450
DegeneratedMY09-ACGT CCM ARR GGA TAC TGA TCPresent Study450
MY09-BCKN CCH ARD GGA AAC TGA TC
MY09-CCKM CCH ARK GGA WTA TGA TC
MY09-DCKD CCY ARD GGR AAT TGG TC
MY11-1GCN GAG GGH CAC AAT AAT GG
MY11-2GCN CAG GGH CAB AAC AAT GG
MY11-3CCH CAR GGH CAT AAT AAT GG
MY11-4GCN CAG GGH CAT AAC AAT GG
MY11-5GCY CAG GGH YWM AAC AAT GG
Constitutive geneBG1CAC CTT TGC CAC ACT GAG TGA GPresent Study366
BG2AGT AAT GTA CTA GGC AGA CTG TG
Nucleotides degeneration: N = A/C/G/T; D = G/A/T; H = A/T/C, R = A/G, K = G/T, M = A/C, W = A/T, Y = C/T, B = C/G/T. * Primer sequences are detailed in patent application PCT/BR2018/050062 filed on 8 March 2018. WellRed D3-PA (685–706 nm) or HEX (5′-Hexachlorofluorescein phosphoramidite; 535–556 nm) are used for detection.
Table 2. Sequences of primers used in the single-tube nested-multiplex PCR assay for the amplification of 40 HPV-specific types, with the β-globin (BG) gene serving as a human constitutive gene internal control.
Table 2. Sequences of primers used in the single-tube nested-multiplex PCR assay for the amplification of 40 HPV-specific types, with the β-globin (BG) gene serving as a human constitutive gene internal control.
Oncogenic RiskHPVAmplicon Size (bp)Oligonucleotide Sequences (5′ -> 3′) 1,2GenBank IdentifierNucleotide Position
Low06319(D4-PA) 3 ACA TGA CAT TAT GTG CAT CCGAF0929326799-6819
CCT CCC AAA AAC TAA GGT TC7119-7100
Low11290(D4-PA) 3 CAT CTG TGT CTA AAT CTG CTAF335603.11028-1047
TAT CCT TAT AGG GAT CCT GT1318-1299
High16175(D4-PA) 3 CTA ACT TTA AGG AGT ACC TACAY1776791073-1093
TCT TCT AGT GTG CCT CCT1247-1230
High18239(D4-PA) 3 TCT CCT GTA CCT GGG CAU45891103-119
GGT AAT AGC AAC AGA TTG TG340-320
High26286CTG ACA GGT AGT AGC AGA GTX744726877-6858
(D3-PA) 3 ACC ACC CGC AGT ACT AAC CTT6592-6613
High30171GGT GAC AAT CCA ATA TTC CAG CX744746871-6850
(D4-PA) 3 CGT TAT CCA CAT ATA ATT CAA GCC6700-6723
High31313(D3-PA) 3 CAA TTG CAA ACA GTG ATA CTU374102737-2717
AAA TTA ACC TCC CAA AAT AC2424-2444
High33315(D3-PA) 3 TTT ATG CAC ACA AGT CAC TAGU45897-M1273284-104
CAC TTC CCA AAA TGT ATA TTT ACC399-376
High34170(D3-PA) 3 ACA ATC CAC AAG TAC AAC TGCX744766542-6562
TCC ACT GTT CCA ATA TAC TAG AA6711-6689
High35277(D3-PA) 3 TG TTC TGC TGT GTC TWC TAGM74117-X744776609-6628
GGT TTT GGT GCA CTG GGT6885-6866
High39237(D2-PA) 3 TAC CTC TAT AGA GTC TTC CAU45905-U4590490-109
AGA CTG TAA GTA TCT GTA AGT G327-306
Low42285(D4-PA) 3 TGT GCC ACT GCA ACA TCT GGM732366869-6888
GGA TCC TTT TTT TCT GGC GTT GT7152-7130
Low43246CAT GCA ATG GCC TTG TTA GACU12504341-321
(D4-PA) 3 CTG ACC CTA CTG TGC CCA G98-116
Low44205TAA GGT ACC ATT TGG GGG CGU12493300-281
(D4-PA) CCA CTA CAC AGT CCC CTC CG95-114
High45193GAA ATC CTG TGC CAA GTA CX74479-U459156662-6680
(D3-PA) 3 TGT AGT AGG TGG TGG AGG G6855-6837
High51337(D4-PA) 3 ACT ATT AGC ACT GCC ACT GM62877-U459176547-6565
AAT CGT TCC TTT AAA TCA ACA TC6884-6862
High52191(D4-PA) 3 CTG AGG TKA AAA AGG AAA GCX744816694-6715
ACG GTG GTG GGG TAA GG6885-6869
High53127(D4-PA) 3 TTC CGC AAC CAC ACA GTCX744826807-6790
TAA CCT CAG CAG ACA GG G6680-6698
Medium54213GTG TGC TAC AGC ATC CAC GCU374886627-6646
(D4-PA) 3 TCC TCC AAA CTA CTT GTA GC6839-6820
Medium55278(D4-PA) 3 CTT TGC CTT TTC AGG GGG AU12494369-351
GCT GCT ACA ACT CAG TCT CC91-110
High56267(D4-PA) 3 TAG TAC TGC TAC AGA ACA GX744836625-6645
TTT GGT GGC TGT TCC CG6892-6878
Low57235(D4-PA)3 AAT ACC TGT AGG TGT CCT GCX559656784-6762
GTC TCT TTG TGT GCC ACT GTA AC6977-6996
High58124(D3-PA) 3 CAC TGA AGT AAC TAA AGA AGAAY09892038-58
CAT TAC CTC TGC AGT TAG TGT164-144
High59213AAG TTA CAG CAG CAG ATT GAAF374230340-321
(D3-PA) 3 CCT ACC AGT TTT AAA GAA TAT GC127-149
Medium61174(D3-PA) 3 ATT TGT ACT GCT ACA TCC CCU317936796-6815
GAG TCA TCC AAC AAG GCC6970-6954
Medium62249GAG ACT CGA AAT AGT GAT ATG TCU12499322-300
(D4-PA) 3 CTA ATT TTA CTA TTT GTA CCG CC74-96
Medium64110TCC ACT GTT CTA ATA TAC TAG AU12495268-247
(D4-PA) 3 TGC AGA AGA GTA TGA CCT CG159-178
High66283CCC AAA ACT TAT ATT TAG CCA GGU01533374-352
(D3-PA) 3 CTA AAT ATG ATG CCC GTG AAA TC92-112
High67141CAT AAC ATT TGC AGT AAG GGAU12492217-196
(D4-PA) 3 AAC ATG ACT TTA TAT TCT GAG G76-97
High68239(D3-PA) 3 TAC TAC TAC TGA ATC AGC TGU4593490-109
CCG CTA TCT GCA ATC AGT312-329
Medium69237(D3-PA) 3 CTA CCC GCA GTA CCA ACC TCAB027020-U124976550-6570
AAC TAG CAG TAG GAG GCA AG6786-6767
Medium70209GCC ATA CCT GCT GTA TAT AGU224611076-1097
(D3-PA) 3 CCT ATA CGT GTC CAC TAAG1285-1267
Medium71202(D3-PA) 3 CTG TGC TAC CAA AAC TGT TGA GAY3306236877-6898
AGC AGT AGG AGG TGG TAA GG7078-7059
Medium7274(D4-PA) 3 ACT ATT TGT ACT GCC ACA GCGX941646819-6839
GTG TGG CGA AGA TAC TCA CG6892-6873
High73180GTA GGT ACA CAG GCT AGT AGAF459425-X9416571-90
(D4-PA) 3 ATT CCA CTC TTC CAA TAT AGT AG250-228
Medium74329(D4-PA) 3 ACA CGY AGT ACT AAC ATG ACW GAF436130-U408226587-6606
AAA TTK GCA TAG GGA TTR GGC6915-6895
Medium81140(D3-PA) 3 CTA TTT GCA CAG CTA CAT CTGEF626590-AJ62020983-103
GTA GGC CAT AAT TTC TGG TGT222-202
High82261(D4-PA) 3 CAT TAG CAC TGC TGY TAC TCCAB0270216599-6619
CCY KKT GAC AGG AKG TTG CTG6859-6844
Medium83305GGA TCC TTT TTA GGG GCA GGU12489374-355
(D4-PA) 3 AGT ACC AAT ATT ACT ATT TCA GC70-92
Medium8483(D4-PA) 3 AGG AAT ACC TAA GAC ATG TGU12490134-153
CA TGA CCT CTG GAG TCA G216-199
β-globinBG2366AGT AAT GTA CTA GGC AGA CTG TGU0131762945-62967
BG3(D3-PA)-AAG CTG CAC GTG GAT CCT GAG62601-62622
1 Nucleotide degeneration: K = G/T, W = A/T, Y = C/T. 2 Primers under the patent application PCT/BR2018/050062, filed on 8 March 2018. 3 Fluorophore-labeled probes (Excitation-Emission): WellRed D4-PA (650–670 nm) or FAM: 6-carboxyfluorescein (495–520 nm). WellRed D3-PA (685–706 nm) or HEX: 5′-Hexachlorofluorescein phosphoramidite (535–556 nm). WellRed D2-PA (750–770 nm) or TAMRA: 6-carboxytetramethylrhodamine (557–583 nm).
Table 3. Comparative results among the HPV diagnostic assays, including the nested-multiplex PCR (NMPCR), Hybrid Capture 2 (HC2), and cytopathological analysis of 40 patients from São Luís, MA, Brazil.
Table 3. Comparative results among the HPV diagnostic assays, including the nested-multiplex PCR (NMPCR), Hybrid Capture 2 (HC2), and cytopathological analysis of 40 patients from São Luís, MA, Brazil.
NMPCR × HC2 × Cytopatholgy
NMPCRTotalHC2Cytopathology
PNP *N
P30 (75.0%)10 (25.0%)20 (50.0%)14 (35.0%)16 (40.0%)
N10 (25.0%)2 (5.0%)8 (20.0%)2 (5.0%)8 (20.0%)
Total40 (100%)12 (30%)28 (70.0%)16 (40.0%)24 (60.0%)
HC2 × CytopathologyP6 (15.0%)6 (15.0%)
N10 (25.0%)18 (45.0%)
Total16 (40.0%)24 (60.0%)
P indicates positive; N indicates negative. * Positive for cervical intraepithelial neoplasia (CIN).
Table 4. Prevalence of HPV genotypes * detected by the NMPCR assay in 3079 infected women out of 5223 (59.0%), Brazil.
Table 4. Prevalence of HPV genotypes * detected by the NMPCR assay in 3079 infected women out of 5223 (59.0%), Brazil.
HPV Genotype/RiskSingle Infection (%)Multiple Infection (%)
High-Risk
(58.6%; 757 out of 1292)		42.0%
(1292 out of 3079)		58.0%
(1787 out of 3079)
164.913.4
181.68.4
260.43.1
302.68.1
315.214.6
331.25.2
341.95.7
354.09.9
391.712.0
451.24.5
513.214.4
525.418.3
537.116.1
563.711.8
663.912.3
670.94.8
680.53.9
690.84.0
701.54.3
733.711.4
820.41.9
Low- and Medium-Risk
(41.4%; 535 out of 1292)
615.127.5
110.93.3
424.516.1
430.31.5
442.48.8
544.016.5
614.615.1
623.110.6
711.64.6
720.10.4
740.20.8
811.27.9
831.24.0
841.53.8
* Five HPV genotypes were observed in very few cases (<0.075%), with genotype 55 in two cases, genotypes 58 and 59 in one case each, and genotypes 57 and 64 in no cases.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Goulart, L.R.; Colombo, B.F.M.; Lima, M.I.S.; de Andrade, M.S.A.; São Julião, J.; Neves, A.F.; Pereira, S.R. Expanded HPV Genotyping by Single-Tube Nested-Multiplex PCR May Explain HPV-Related Disease Recurrence. Microorganisms 2024, 12, 2326. https://doi.org/10.3390/microorganisms12112326

AMA Style

Goulart LR, Colombo BFM, Lima MIS, de Andrade MSA, São Julião J, Neves AF, Pereira SR. Expanded HPV Genotyping by Single-Tube Nested-Multiplex PCR May Explain HPV-Related Disease Recurrence. Microorganisms. 2024; 12(11):2326. https://doi.org/10.3390/microorganisms12112326

Chicago/Turabian Style

Goulart, Luiz Ricardo, Bruna França Matias Colombo, Mayara Ingrid Sousa Lima, Maria Socorro A. de Andrade, Juliana São Julião, Adriana Freitas Neves, and Silma Regina Pereira. 2024. "Expanded HPV Genotyping by Single-Tube Nested-Multiplex PCR May Explain HPV-Related Disease Recurrence" Microorganisms 12, no. 11: 2326. https://doi.org/10.3390/microorganisms12112326

APA Style

Goulart, L. R., Colombo, B. F. M., Lima, M. I. S., de Andrade, M. S. A., São Julião, J., Neves, A. F., & Pereira, S. R. (2024). Expanded HPV Genotyping by Single-Tube Nested-Multiplex PCR May Explain HPV-Related Disease Recurrence. Microorganisms, 12(11), 2326. https://doi.org/10.3390/microorganisms12112326

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop